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http://dxObjective: Pay-for-performance measures, part of the Affordable Care Act, aim to reduce health care costs by
linking value with Medicare payments, but until now the concept of value has not been applied to specific
procedures. We sought to define value in coronary artery bypass grafting (CABG) and provide a framework
to identify high-value centers.
Methods: In a multiinstitutional statewide database, clinical patient-level data from 42,839 patients undergoing
CABG were matched with cost data. Hierarchical models adjusting for relevant preoperative patient character-
istics and comorbidities were used to estimate center-specific risk-adjusted costs and risk-adjusted postoperative
length of stay. Variation in value across centers was assessed by the correlation between risk-adjusted measures
of quality (mortality, morbidity/mortality) and resource use (costs and length of stay).
Results: There were no significant correlations between risk-adjusted costs and risk-adjusted mortality
(r ¼ 0.20, P ¼ .45) or morbidity/mortality (r ¼ 0.15, P ¼ .57) across centers. Risk-adjusted costs and length
of stay were not significantly associated (r ¼ 0.23, P ¼ .37) because of cost accounting differences across
centers. This may explain the lack of correlation between risk-adjusted quality and risk-adjusted cost measures.
When risk-adjusted length of stay and morbidity/mortality were used for the framework, there was a strong
positive correlation (r ¼ 0.67, P ¼ .003), indicating that higher risk-adjusted quality is associated with shorter
risk-adjusted length of stay.
Conclusions: Risk-adjusted length of stay and risk-adjusted combined morbidity/mortality are important
outcome measures for assessing value in cardiac surgery. The proposed framework can be used to define
value in CABG and identify high-value centers, thereby providing information for quality improvement and
pay-for-performance initiatives. (J Thorac Cardiovasc Surg 2014;148:2729-35)Supplemental material is available online.A
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The Journal of Thoracic and Carproportion is nearly 18% (almost US$3 trillion) in the
United States.1,2 There is wide consensus that we must
contain health care expenditure while improving quality,
and numerous approaches focusing on value have been
proposed.3,4 Pay-for-performance measures and value-
based payment modifiers, to be implemented in 2015 as
part of the Affordable Care Act, aim to reduce health care
costs by linking quality and resource use performance
measures with Medicare payments to physicians and
hospitals. Physicians will be held accountable for resource
utilization and costs for their hospitalized patients.
With more than 200,000 costly procedures performed in
the United States annually, coronary artery bypass grafting
(CABG) is an important procedure for improving health
care value.5 Value can be defined by a combination of clin-
ical quality and resource use and should use risk-adjusted
measures.4,6 Although comparisons in efficiency exist7
and quality assessment measures have been proposed,8-10
the concept of value (combining risk-adjusted measures
of resource use and quality) has not been applied to specific
procedures like CABG.
We conducted a study to define value in CABG and to
provide a framework to identify high-value centers. By
adjusting for relevant preoperative patient characteristics
and comorbidities, we derived measures of risk-adjusteddiovascular Surgery c Volume 148, Number 6 2729
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CMS ¼ Centers for Medicare andMedicaid
Services
STS ¼ Society of Thoracic Surgeons
STS-PROM ¼ Society of Thoracic Surgeons-
predicted risk of mortality
STS-PROMM ¼ Society of Thoracic Surgeons-
predicted risk of morbidity or
mortality
UB ¼ Uniform billing
VCSQI ¼ Virginia Cardiac Surgery Quality
Initiative
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Dresource use and risk-adjusted quality after CABG. Subse-
quently, we tested whether higher risk-adjusted quality was
correlated with shorter risk-adjusted length of stay and
lower risk-adjusted costs.METHODS
The Virginia Cardiac Surgery Quality Initiative (VCSQI) database was
used for this analysis. Clinical records of patients undergoing cardiac
surgery were collected prospectively and all primary isolated CABGs
between January 2003 and April 2013 were selected for the current study.
VCSQI is a voluntary group of 17 cooperating cardiac surgery centers in
the Commonwealth of Virginia.11 The aim of the consortium is to improve
the quality of cardiac surgical care, while reducing costs. The database
covers100% of all cardiac surgical procedures in the state. VCSQImem-
bers contribute their data to the Society of Thoracic Surgeons (STS) Adult
Cardiac Database. Each of VCSQI’s centers agreed to share deidentified
patient data for secondary research and quality improvement. Institutional
review boards at each participating center exempted this study because it
represents a secondary analysis of the VCSQI data registry in the absence
of Health Insurance Portability and Accountability Act patient identifiers.
Business Associates Agreements are in place between VCSQI, its 17 mem-
bers, and the database vendor (ARMUS Corporation, San Mateo, Calif).
Clinical Data
Postoperative outcomes were routinely collected in the STS database
and included death, stroke, renal failure, atrial fibrillation, deep sternal
wound infection, permanent stroke, prolonged ventilation, and reopera-
tions for bleeding, graft occlusion, and other reasons, all defined according
to the STS database definitions.12 Operative death was defined as death
within 30 days after discharge or within the hospital stay. Preoperative
risk was assessed using the STS-predicted risk of mortality (STS-PROM)
and the STS-predicted risk of morbidity or mortality (STS-PROMM).
Each center was responsible for coding and submitting its data to VCSQI
and agreed on the definitions, data collection, and timely submission.
Cost Data
Patient-level clinical and financial data in the VCSQI database were com-
bined as previously described.13,14 Briefly, STS patient recordswerematched
with uniform billing (UB) discharge records. The UB-04 form is used
throughout the United States and represents the patient’s final hospital bill.
Charges for all of the ICD-9 (International Classification of Diseases, ninth
revision) revenue codes were grouped into 20 logical cost categories (Table
E1). Because charges reflect institutional pricing decisions and other factors2730 The Journal of Thoracic and Cardiovascular Surunrelated to resource use, we applied cost-to-charge ratios.15 These ratios
were updated annually and were specific for each participating institution
and category within that institution. The total costs estimate was the sum
of all 20 categories. The variation in total costs and postoperative length of
stay as a result of postoperative complications was reflected in the total esti-
mate for the individual patient.14 The medical care service component of the
US consumer price index was used to convert all costs to US dollars for the
year 2013.13,16
Statistical Analysis
We calculated risk-adjusted costs and postoperative length of stay for
each of the 17 centers by adjusting for differences in the patient case
mix. Risk-adjusted estimates were derived from hierarchical models,
which account for clustering of outcomes within hospitals, provide more
stable estimates for hospitals with low volumes, and adjust for multiplicity
of comparisons. This approach to risk standardization has been gaining
increasing traction in recent years and has been adopted by Centers for
Medicare andMedicaid Services (CMS).17 We modeled cost and postoper-
ative length of stay as dependent variables, applying hierarchical general-
ized linear models, with a gamma distribution for costs and a negative
binomial distribution for length of stay.18 These models included a random
effect for hospital and adjustment for preoperative patient characteristics
and comorbidities (Table E2). Given the iterative modeling and large
number of variables included, only variables that were significant at a level
of P  .01 were preserved in the models.19 The variables age, gender, and
race were forced into the models. The models were recently validated for
prediction of postoperative length of stay and costs.19 Regressions were
estimated in log and linear form, and reported in linear form, because there
were no substantial differences in the results and linear regression
coefficients are more easily interpreted.
Hospital mean risk-adjusted costs were derived by calculating the ratio
of average model-predicted costs for a given hospital to the expected costs
based only on patient characteristics, and then multiplying this ratio by the
average cost of the overall population. Hospital mean risk-adjusted lengths
of stay were calculated in a similar way.20-22 Risk-adjusted measures of
mortality and morbidity/mortality were also calculated per center, based
on validated STS risk calculators.
Morbidity/mortality was defined as postoperative deep sternal wound
infection, reoperation, permanent stroke, prolonged ventilation, renal fail-
ure or operative mortality.8,9,12 Correlation between risk-adjusted quality
and resource use measures were assessed with the Spearman correlation
coefficient. Analyses were performed using Excel 2010 (Microsoft,
Redmond, Wash) and SPSS version 20.0.0 (SPSS, Chicago, Ill), and the
hierarchical models were fitted using the GLIMMIX macro in SAS 9.3
(SAS Institute, Inc, Cary, NC).
RESULTS
The patient characteristics and comorbidities of the
42,839 patients who underwent CABG are presented in
Table 1. The STS-PROM averaged 2.2% and the STS-
PROMM was 13.8%. Postoperative clinical outcomes and
resource use are presented in Table 2. Atrial fibrillation
was the most common postoperative complication
(17.2%), followed by prolonged ventilation (9.3%) and
renal failure (3.5%). Mean total length of stay was 9.3
days, most of which consisted of postoperative stay (6.9
days). The mean total costs for CABG were US$38,848.
There was significant variation in risk-adjusted costs
(US$27,380-55,296), risk-adjusted postoperative length
of stay (6.26-8.77 days), risk-adjusted mortality
(0.95%-2.13%), and risk-adjusted morbidity/mortalitygery c December 2014
TABLE 1. Patient characteristics
Characteristic N ¼ 42,839
Age, y  SD 64.0  10.7
Male sex,% 73.7
STS-PROM 2.17  3.7
STS-PROMM 13.80  10.6
Race,%
White 81.5
African American 13.8
Hispanic 0.8
Asian 2.4
Native American 0.1
Other 1.4
Body mass index, kg/m2 29.4  5.7
Heart failure 2 wk before,% 12.0
Renal failure requiring dialysis,% 2.3
Creatinine, mg/dL 1.20  1.0
Left ventricular ejection fraction 51.3  12.5
Chronic lung disease,%
No 82.4
Mild 10.0
Moderate 5.0
Severe 2.5
Cerebrovascular disease,% 13.5
Preoperative cardiogenic shock,% 1.6
Urgency status,%
Elective 41.5
Urgent 54.9
Emergency 3.6
On inotropic medication,% 1.6
Arrhythmia,% 7.5
Myocardial infarction 21 d,% 29.0
Peripheral arterial disease,% 14.2
Hypertension,% 81.4
Diabetes mellitus,% 39.6
Immunocompromised status,% 2.1
Previous CABG,% 3.2
Previous valve operation,% 0.2
Previous PCI,% 18.7
No. of diseased vessels,%
1 4.2
2 17.6
3 78.1
Data defined as the mean  standard deviation or % of patients. SD, Standard
deviation; STS-PROM, Society of Thoracic Surgeons-Predicted Risk of Mortality;
STS-PROMM, Society of Thoracic Surgeons-Predicted Risk of Mortality or
Morbidity;CABG, coronary artery bypass grafting; PCI, percutaneous coronary inter-
vention.
TABLE 2. Postoperative clinical outcomes and resource use
Variable N ¼ 42,839
Postoperative ventilation>24 h 9.3
Postoperative renal failure 3.5
Postoperative pneumonia 2.9
Postoperative atrial fibrillation 17.2
Postoperative stroke 1.4
Postoperative deep sternal wound infection 0.4
Reoperation bleeding 1.7
Reoperation other cardiac reasons 0.8
Reoperation noncardiac reasons 2.0
Operative mortality 1.8
Operative morbidity/mortality* 14.4
Total length of stay, d 9.3  7.9
Postoperative length of stay, d 6.9  7.0
Total costs, US$  SD [median] 38,848  29,299 [32,397]
Data defined as mean  SD, or% of patients. SD, Standard deviation. *Defined as
operative deep sternal wound infection, reoperation, permanent stroke, prolonged
ventilation, renal failure, or mortality.
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D(10.78%-19.44%) across centers. Figure 1, A, presents a
plot of risk-adjusted costs versus risk-adjusted mortality,
showing that there was no statistically significant
correlation between risk-adjusted costs and risk-adjusted
mortality (r ¼ 0.20, P ¼ .45). Also when complications
were included in the risk-adjusted outcome, we found no
statistically significant correlation (risk-adjusted costs vs
risk-adjusted morbidity/mortality; r ¼ 0.15, P ¼ .57;
Figure 1, B).The Journal of Thoracic and CarFigure 2, A, presents a plot of risk-adjusted postoperative
length of stay and risk-adjusted mortality for the 17 cardiac
surgical centers. The correlation between risk-adjusted
length of stay and risk-adjusted mortality was not statisti-
cally significant (r ¼ 0.27, P ¼ .30). This suggests that
lower mortality is not associated with lower resource use,
as measured by postoperative length of stay.
There was a significant positive correlation between
the more comprehensive quality outcome measure, risk-
adjusted morbidity/mortality, and risk-adjusted length of
stay (r ¼ 0.67, P ¼ .003; Figure 2, B). Also when 2 centers
with the highest risk-adjusted length of stay were excluded,
the correlation remained positive and significant (r ¼ 0.60,
P ¼ .02). This suggests that higher quality (low risk-
adjusted morbidity/mortality) coincides with shorter
postoperative length of stay. Those cardiac surgical
centers represent high-value CABG. On the contrary, there
were also centers in the upper right quadrant that
combined high risk-adjusted morbidity/mortality with
high risk-adjusted length of stay. This suggests that lower
quality, as measured by higher than expected morbidity
and mortality, leads to higher resource use, as measured
by higher than expected postoperative length of stay. It is
these centers that represent low value.
There was no significant correlation between risk-
adjusted costs and risk-adjusted length of stay across
centers (r ¼ 0.23, P ¼ .37; Figure 3). Although there
were several centers for which the risk-adjusted costs and
risk-adjusted length of stay showed a trend (centers A, O,
B, I, J, P, L, E, and N), there were also centers (C, K, D,
and M) that had risk-adjusted costs that were different
than would be expected based on risk-adjusted length of
stay. Because length of stay is closely related to costs at a
group level,23 a strong correlation between risk-adjusted
cost and risk-adjusted length of stay was expected.diovascular Surgery c Volume 148, Number 6 2731
FIGURE 1. Risk-adjusted costs versus risk-adjusted mortality (A) and versus risk-adjusted morbidity/mortality (B) per center. The lack of a statistically
significant correlation coefficient indicates that there is no relationship between resource use (risk-adjusted postoperative length of stay) and quality (risk-
adjusted mortality and risk-adjusted morbidity/mortality). The axes cross at the population average operative mortality (1.80%) and population average
costs (US$38,848). Int, Intermediate; morbi, morbidity.
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DDISCUSSION
Even after adjusting for preoperative patient characteris-
tics and comorbidities, we found important variation in
measures of quality (risk-adjusted mortality, risk-adjusted
morbidity/mortality) and resource use (risk-adjusted costs
and risk-adjusted length of stay) across 17 centers perform-
ing CABG in the Commonwealth of Virginia. A significant
correlation existed between risk-adjusted morbidity/mortal-
ity and risk-adjusted length of stay. These findings suggest
that better quality leads to shorter postoperative length of
stay and resource use. Substantial savings and better
outcomes can be realized if all centers achieve the same
performance as high-value centers.
This is the first study to describe combined, center-
specific, clinical, and financial outcomes for CABG. TheFIGURE 2. Risk-adjusted length of stay versus risk-adjusted mortality (A) an
correlation between risk-adjusted postoperative length of stay and risk-adjuste
adjusted length of stay and risk-adjusted morbidity/mortality indicates that ce
more efficient (low risk-adjusted length of stay), thereby representing high-va
(14.40%) and population average costs (US$38,848). Int, Intermediate; LOS, l
2732 The Journal of Thoracic and Cardiovascular Surover- and underperforming centers are shown in the lower
left and upper right quadrants in Figure 2, B, respectively.
The study serves as a basis for discussions on health care
value measurement and facilitates improvements of value
in health care. Policy measures as pay-for-performance and
the value-based payment modifiers provide financial incen-
tives to improve value (ie, to keep costs low by improving
outcomes and quality of care).24,25 In general, policy
measures will provide incentives that relate payment
inversely to risk-adjusted clinical outcomes and risk-
adjusted resource use. In the current study, we found distinct
variability invaluewhen both quality and costmeasureswere
combined, but the exact definitions of low/high performers
require close collaboration with the physician community
before this can lead to real-world payment implications.d risk-adjusted morbidity/mortality (B) per center. There is no significant
d mortality. The significant positive correlation coefficient between risk-
nters with higher quality (low risk-adjusted morbidity/mortality) are also
lue centers. The axes cross at the population average morbidity/mortality
ength of stay; morbi, morbidity.
gery c December 2014
FIGURE 3. Risk-adjusted costs and risk-adjusted length of stay per center. The dots represent the risk-adjusted costs (vertical axis) and risk-adjusted length
of stay (horizontal axis) per cardiac surgical center. LOS, Length of stay.
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DPrevious studies on pay-for-performance have been
criticized for their performance metrics that focused on pro-
cesses of care that were not clinically meaningful.26 For
instance, measuring the proportion of patients with heart
failure receiving paper discharge instructions does not
necessarily result in better patient outcomes.27 In general,
physicians, patients, and the CMS should work together
to define meaningful outcome measures. Clinically relevant
metrics will not only increase the potential of pay-for-
performance but are also more likely to engage physicians
than process-based metrics.28 In the current analyses, we
used risk-adjusted costs and risk-adjusted length of stay
as measures of resource use, and risk-adjusted mortality
and risk-adjusted morbidity/mortality as quality measures.
Outcome Measures for Assessing Value
Unexpectedly, we only found a strongly significant corre-
lation when risk-adjusted length of stay and risk-adjusted
morbidity/mortality were used as outcome measures for
resource use and quality, respectively. Because costs and
length of stay are closely related at a group level,23 we
also expected risk-adjusted costs and risk-adjusted
morbidity/mortality to be significantly correlated. However,
different centers account costs differently, particularly in
the way overhead costs are allocated.29 A center with brand
new facilities and high real estate costs may allocate costs
differently to a single procedure (CABG) than centers
with depreciated facilities and a lower cost location. This
is less of an issue when the study objective is to estimate
overall costs of a procedure or model building for all centers
combined,19 but using these cost data to compare centers is
likely to reflect the variation in accounting systems insteadThe Journal of Thoracic and Carof true differences in the efficiency of performing CABG.
Even with a uniform hospital bill (UB-04) and similar
cost accounting systems, it is not clear that the accounting
practices are comparable across each of the study centers,
because costs of similar resources (catheters, sutures,
equipment) might also differ between centers. Ideally,
standardized unit costs should be applied to each patient’s
resource consumption,30 but these data were unavailable
for this large dataset.
Our alternative measure of risk-adjusted resource use,
length of stay, is widely available and easy to measure.
Postoperative length of stay as an isolated performance
measure (ie, without a risk-adjusted qualitymeasure) should
be avoided, because this might lead to overaggressive
discharge protocols.31 A balanced approach to efficiency
and quality improvement will provide a patient centric and
patient safe approach to health care. Also, factors beyond
a hospital’s direct control (eg, the lack of postacute facilities)
might influence postoperative length of stay. On the other
hand, risk-adjusted length of stay (in combination with
risk-adjusted quality) provides incentives for centers to care-
fully evaluate their processes of care from a broad perspec-
tive, including improvements in postdischarge facilities.
We did not find a correlation of risk-adjusted mortality
with any measure of risk-adjusted resource use (costs or
length of stay). Mortality alone may be an inadequate
measure to compare quality across centers and our analyses
show that complications are the real driver of the associa-
tion. Mortality may or may not result in increased resource
use because a patient who dies shortly after surgery
consumes few resources. Complications on the other
hand, always lead to higher resource use consumption.diovascular Surgery c Volume 148, Number 6 2733
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DTherefore, the STS Quality Measurement Task Force
proposes a comprehensive composite quality score, in
which risk-adjusted morbidity/mortality is an important
domain.8,9
After high-value centers have been identified, subsequent
in-depth research and comparison with low-value centers is
needed to identify factors that help to explain how these
centers achieved the exceptional performance on risk-
adjusted quality and risk-adjusted resource use measures.
This process of quality improvement could include qualita-
tive research such as collaborative site visits and structured
interviews between the participating centers.8,9
Limitations
This study has some limitations. First, the results of this
study may not be generalizable to other cardiac surgical
centers in the United States as data were used from 17 car-
diac surgical centers in 1 state. However, the key variables
(STS-PROMM, length of stay) are well known and there-
fore, the framework developed in this study can be applied
to all cardiac surgical centers in the United States perform-
ing CABG. Second, we used postoperative length of stay as
a surrogate for resource use because differences in account-
ing methodology hampered cost comparisons across
centers. Ideally, standardized unit costs should be applied
to each patient’s resource consumption.30 However, these
detailed individual resource consumption data were
unavailable for this large dataset. Instead, we used a single
measure of resource use, risk-adjusted length of stay, which
is closely related to costs at a group level.23 Third, the study
is observational, and unmeasured confounding cannot be
excluded. However, the risk-adjustment of length of stay
and costs using the available variables was robust, and an
observational design is best to evaluate actual clinical
practice. It is important to realize that centers that treat
markedly more frail or other special patients might be
unjustifiably categorized as a low-value center.
CONCLUSIONS
Risk-adjusted length of stay and risk-adjusted combined
morbidity/mortality are important outcome measures for
assessing value in cardiac surgery. In high-value centers,
lower rates of risk-adjusted morbidity/mortality outcomes
were associated with shorter risk-adjusted length of stay.
The proposed framework can be used to define value in
CABG and identify high-value centers, thereby providing
useful information for quality improvement and pay-for-
performance initiatives.
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TABLE E1. Cost categories and ICD-9 revenue codes
Cost category Revenue codes
Emergency room 450-459
ICU/CCU 200-219
Regular room 100-179
Radiology 320-359, 400-409
Laboratory 300-319
Cardiac diagnostics 480, 482-489, 730-731, 739
Peripheral vascular laboratory 921
Anesthesia 370-379
Operating room 360-369, 490-499
Recovery room 710-719
Blood products 380-399
Implants (pacers, ICD, valve) 275, 278
General supplies 270-274, 276-277, 279
Pharmacy 250-259
Intravenous 260-269
Respiratory therapy 410-419
Cardiac catheterization
laboratory
481
Therapies (PT, OT, cardiac
rehabilitation)
420-449
Dialysis 800-809, 820-859, 880-889
Other 180-199, 220-249, 280-299, 470-479,
500-679, 700-709, 740-799, 901-920,
922-942, 944-999
ICU, Intensive care unit; CCU, cardiac care unit; ICD, implantable cardioverter
defibrillator; PT, physiotherapy; OT, occupational therapy.
TABLE E2. Preoperative patient characteristics and comorbidities
for which the cost and length of stay outcomes were adjusted
Cost model Length of stay model
Age Age
Male sex Male sex
Race Race
Body mass index Body mass index
Heart failure 2 wk before Heart failure 2 wk before
Creatinine Creatinine, mg/dL
Left ventricular ejection fraction Left ventricular ejection fraction
Chronic lung disease (mild/
moderate/severe)
Chronic lung disease (mild/
moderate/severe)
Cerebrovascular disease Cerebrovascular disease
Preoperative cardiogenic shock Preoperative cardiogenic shock
Urgency status (urgent/emergency) Urgency status (urgent/emergency)
On inotropic medication On inotropic medication
Arrhythmia Arrhythmia
Myocardial infarction 21 d Myocardial infarction 21 d
Peripheral arterial disease Peripheral arterial disease
Hypertension —
Diabetes mellitus Diabetes mellitus
Immunocompromised status Immunocompromised status
Previous CABG Previous CABG
Previous valve operation Previous valve operation
Previous PCI —
No. of diseased vessels (2 or 3) No. of diseased vessels (2 or 3)
CABG, Coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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